Table II.

Response to treatment with leflunomide among patients with vasculitis.

	All patients	Type of vasculitis
		GPA	MPA	EGPA	GCA	TAK	PAN
Number of patients (%)	93	45	8	12	14	9	5
Efficacy at 6 months	62 (67%)	31 (69%)	6 (75%)	4 (33%)	9 (64%)	8 (89%)	4 (80%)
Reason for treatment inefficacy
Active disease	19 (20%)	7 (16%)	-	6 (50%)	4 (29%)	1 (1%)	1 (20%)
Adverse events	12 (13%)	7 (16%)	2 (25%)	2 (17%)	1 (7%)	0	0
Sustained remission at 12 months	54 (58%)	27 (63%)	6 (75%)	4 (33%)	7 (54%)	8 (89%)	3 (60%)
Sustained remission at 24 months	46 (50%)	23 (58%)	5 (71%)	4 (33%)	7 (54%)	7 (88%)	2 (40%)

Given percentages are for the proportion of patients in each type of vasculitis with available data, which was incomplete at 12 and/or 24 months for 7 individuals (2 lost to follow-up after 12 months [MPA and TAK]; 4 had not yet reached 12 and/or 24 months with LEF [3 GPA and 1 GCA]; one with GPA died of natural causes before 24 months of LEF).

EGPA: eosinophilic granulomatosis with polyangiitis; GCA: giant cell arteritis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; PAN: polyarteritis nodosa; TAK: Takayasu’s arteritis.